Bruker takes majority stake in organ-on-a-chip developer MIMETAS

• Bruker took a majority stake in MIMETAS, expanding into organ-on-a-chip microphysiological systems for drug discovery and preclinical testing.
• MIMETAS’ OrganoPlate platform provides scalable, high-throughput human tissue models designed to improve disease modeling, drug testing, and safety assessment.
• The deal aims to combine these models with Bruker’s multiomics, NMR, spatial biology, and preclinical imaging to build integrated research workflows.
• Financial terms were not disclosed; MIMETAS will keep its brand and management.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100700BIZWIRE_USPR_____20260810_BW455540) on August 10, 2026, and is solely responsible for the information contained therein.